Literature DB >> 22011671

Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis.

Xiao Li1, Liyan Wan, Hong Shen, Jian Geng, Jing Nie, Guobao Wang, Nan Jia, Meng Dai, Xiaoyan Bai.   

Abstract

INTRODUCTION: Thyroid transcription factor-1 (TTF1) plays a role in lung adenocarcinoma development. We investigated the significance of TTF1 in primary lung adenocarcinomas, lymph node metastases, and malignant pleural effusions (MPEs).
METHODS: We studied TTF1 in 175 primary lung adenocarcinomas, 52 lymph node metastases, and 46 MPE using microarray-based fluorescence in situ hybridization, immunohistochemistry, and messenger RNA (mRNA) in situ hybridization. Real-time reverse transcription polymerase chain reaction was used to investigate correlations between TTF1 amplification and mRNA expression. Correlations between clinicopathologic characteristics, TTF1 amplification, TTF1 expressions, overall survival, and prognosis were analyzed.
RESULTS: TTF1 was amplified in 7% of primary lung adenocarcinomas, 4% of lymph node metastases, and 4% of MPE. TTF1 amplification in lung adenocarcinomas was associated with pathologic subtypes (p = 0.029). Patients with positive TTF1 protein and mRNA expressions had improved overall survival if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). A multivariate model did not show patients with positive TTF1 expressions tended to have better prognoses if TTF1 was unamplified compared with those with TTF1 amplification (p = 0.068). Survival time was longer for patients with TTF1 expressions in both primary lung tissues (p < 0.001) and MPE (p = 0.045). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma (p < 0.001). A multivariate model confirmed the prognostic value of TTF1 expressions in lung adenocarcinoma tissues (p < 0.001) while not in MPE (p = 0.058). TTF1 mRNA level was higher in cases with TTF1 amplification compared with those without TTF1 amplification.
CONCLUSIONS: Patients with lung adenocarcinoma without TTF1 amplification tend to have better prognoses than those with TTF1 amplification in cases with positive TTF1 expressions. Positive TTF1 expressions in lung adenocarcinoma tissues are favorable prognostic parameters in patients with lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22011671     DOI: 10.1097/JTO.0b013e318232b98a

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  14 in total

1.  Comparison of immunohistochemistry and mRNA in situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue.

Authors:  Huiyong Jiang; Xiaoyan Bai; Fanjun Meng; Xuefeng Zhang
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

2.  EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.

Authors:  Z Q Xu; L Zhang; B S Gao; Y G Wan; X H Zhang; B Chen; Y T Wang; N Sun; Y W Fu
Journal:  Clin Transl Oncol       Date:  2014-07-02       Impact factor: 3.405

3.  Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma.

Authors:  Haofei Wang; Wujun Wang; Xuelian Wang; Kaican Cai; Hua Wu; Qun Ju; Zhiyong Huang; Xuhui Gao
Journal:  Med Oncol       Date:  2012-04-22       Impact factor: 3.064

4.  Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Inderpal S Sarkaria; Camelia S Sima; Xiaoyu Jia; Akihiko Yoshizawa; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

5.  Diagnostic value of thyroid transcription factor-1 for pleural or other serous metastases of pulmonary adenocarcinoma: a meta-analysis.

Authors:  Yongchun Shen; Caishuang Pang; Konglong Shen; Yanqiu Wu; Diandian Li; Chun Wan; Zenglin Liao; Ting Yang; Lei Chen; Fuqiang Wen
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

6.  Prognostic relevance of TTF-1 expression in stage I adenocarcinoma.

Authors:  Chao Zhou; Jikai Zhao; Jinchen Shao; Wentao Li
Journal:  Oncotarget       Date:  2017-11-18

7.  Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis.

Authors:  Jung Han Kim; Hyeong Su Kim; Bum Jun Kim; Boram Han; Dae Ro Choi; Jung Hye Kwon
Journal:  J Cancer       Date:  2018-10-20       Impact factor: 4.207

8.  The clinical significance of Psoriasin for non-small cell lung cancer patients and its biological impact on lung cancer cell functions.

Authors:  Mu Hu; Lin Ye; Fiona Ruge; Xiuyi Zhi; Lijian Zhang; Wen G Jiang
Journal:  BMC Cancer       Date:  2012-12-10       Impact factor: 4.430

9.  Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole nuclei, and its clinicopathological significance.

Authors:  Huiyong Jiang; Xiaoyan Bai; Fanjun Meng; Cheng Zhang; Xuefeng Zhang
Journal:  Oncol Lett       Date:  2014-03-28       Impact factor: 2.967

10.  MicroRNA-130b promotes lung cancer progression via PPARγ/VEGF-A/BCL-2-mediated suppression of apoptosis.

Authors:  Jianwei Tian; Liping Hu; Xiao Li; Jian Geng; Meng Dai; Xiaoyan Bai
Journal:  J Exp Clin Cancer Res       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.